Circulating cell-free DNA (cfDNA) is being widely researched for use as a biomarker for various types of cancer, autoimmune diseases, and chromosomal disorders. All cells shed small DNA fragments into the blood stream as they undergo apoptosis or necrosis. Tumor cells shed DNA at higher concentrations than non-tumor cells, and the fragments contain somatic mutations that can be detected via sequencing. One of the advantages of analyzing cfDNA is that it can be easily obtained from a blood draw, providing a “liquid biopsy” option that is less invasive than traditional biopsy techniques. The cfDNA is then isolated from the blood sample, quantitated, sequenced, and analyzed.